stockrow
Saturday 7 November 2026
Export COCP’s income statement to Excel — free account
Cocrystal Pharma, Inc.
COCP Healthcare Biotechnology
- Revenue
- −81.1%
- EPS
- −15.0%
- Free cash flow
- −16.8%
Quarter to June 2026, against a year earlier
1.04
0.04
+4.00%
Follow COCP
Alert me
Cocrystal Pharma, Inc. (COCP) P/E ratio
Cocrystal Pharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 1,158× (April 2018) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2020 | 0.0× | — |
| Sep 2020 | 0.0× | — |
| 9 more quarters | Free account |
Against its own ten years
Low 0.0×
High 1,158×
Ten-year median
0.0×
Current reading's percentile
95
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ATOS Atossa Therapeutics, Inc. compare | n/m |
| ACTU Actuate Therapeutics, Inc. compare | n/m |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | n/m |
| MCRB Seres Therapeutics, Inc. compare | n/m |
| ESLA Estrella Immunopharma, Inc. compare | n/m |
| KTTA Pasithea Therapeutics Corp. compare | n/m |
| COCP Cocrystal Pharma, Inc. | n/m |
| BSEM BioStem Technologies, Inc. compare | n/m |
| IMMP Prima BioMed Ltd compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)